Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
Clinical trial NCT03381430 · UNKNOWN
Trial details
- NCT number
- NCT03381430
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-01
- Primary completion
- 2023-03-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.